A Phase 3 interventional study of Rifaximin in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Completed at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 3, and was the 5th registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Belgium, Netherlands
Ages 18–80
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2007.
This study's enrollment of 322 is above the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 94 across the 18 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 7 studies filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing rifaximin in Hepatic Encephalopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
Eligible participants had a history of HE, a Conn score of 0 to 2 at enrollment, and either had successfully participated in a previous HE study with rifaximin (that is, RFHE3001 [NCT00298038]), or were new participants enrolled with ≥1 verifiable episode of HE (equivalent to a Conn score of ≥2) associated with cirrhosis or portal hypertension within 12 months of screening.
Successful participation in a previous rifaximin study was defined as having received ≥80% and ≤120% of the expected tablets, having been reasonably compliant with study procedures, and having not been discontinued from the previous study due to study drug-related Adverse Events. Participants who experienced HE or associated symptoms during or after the RFHE3001 study were considered eligible for entry into this open-label study if the participant and Investigator did not perceive study medication as a possible cause of the HE episode or associated symptoms. Participants who did not participate in a previous HE study with rifaximin were eligible if this open-label study was the only rifaximin HE study available at an individual site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
Drug: Rifaximin
Oral
Also known as: Xifaxan®
Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event
A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to Month 36
Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants
Hematology and blood chemistry with potentially significant values included: Hemoglobin \<9, \>18, or ≥3 (grams/deciliter \[g/dL\]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit \<0.27%, \>0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets \<50 or \>400\*10\^9/(liter \[L\]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio \>1.7; White blood cells \<2.0 or \>12.0\*10\^9/L; Lymphocytes \<13.5% or \>70%; Glucose, random, serum \<2.2 or \>16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or \>85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to Month 36
Number Of Participants With A Significant Mean Change From Baseline In Vital Signs
Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to Month 36
Change From Baseline In Conn Score At Last Assessment
The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug.
Time frame: Baseline up to Month 36
A total of 152 (47%) participants with hepatic encephalopathy (HE) rolled over from the double-blind study RFHE3001 (NCT00298038); 70 rifaximin participants (designated to the "Continued Rifaximin" arm in Study RFHE3002) and 82 placebo participants (designated to the "New Rifaximin" arm along with the new 170 \[53%\] participants in Study RFHE3002).
| Milestone | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Started | 252 | 70 |
| Received at least 1 dose of study drug | 252 | 70 |
| Completed | 120 | 34 |
| Not completed | 132 | 36 |
| Withdrew: Death | 45 | 14 |
| Withdrew: Liver transplant | 23 | 8 |
| Withdrew: Recurrent hepatic encephalopathy episode | 1 | 2 |
| Withdrew: Withdrawal by subject | 23 | 5 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Adverse event | 10 | 2 |
| Withdrew: Personal reason | 0 | 1 |
| Withdrew: Lost to follow-up | 15 | 3 |
| Withdrew: Moved to another state | 1 | 0 |
| Withdrew: Transferred to nursing home | 1 | 0 |
| Withdrew: Noncompliance | 9 | 0 |
| Withdrew: Principal investigator decision | 2 | 0 |
Hematology and blood chemistry with potentially significant values included: Hemoglobin \<9, \>18, or ≥3 (grams/deciliter \[g/dL\]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit \<0.27%, \>0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets \<50 or \>400\*10\^9/(liter \[L\]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio \>1.7; White blood cells \<2.0 or \>12.0\*10\^9/L; Lymphocytes \<13.5% or \>70%; Glucose, random, serum \<2.2 or \>16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or \>85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Hemoglobin | 15 | 12 |
| Hematocrit | 12 | 4 |
| Platelets | 18 | 6 |
| Prothrombin Time | 16 | 7 |
| International Normalized Ratio | 24 | 8 |
| White Blood Cells | 15 | 2 |
| Lymphocytes | 24 | 10 |
| Glucose, random, serum | 8 | 8 |
| Potassium | 17 | 7 |
| Direct Bilirubin | 14 | 5 |
A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Non-Serious Adverse Event | 78 | 15 |
| Serious Adverse Event | 158 | 49 |
Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Number Of Participants With A Significant Mean Change From Baseline In Vital Signs | 0 | 0 |
The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug.
| score on a scale | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Baseline | 0.4 ± 0.58 | 0.2 ± 0.40 |
| Change from Baseline | -0.1 ± 0.77 | 0.1 ± 0.41 |
Collected over Baseline up to Month 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| New Rifaximin | — | 158/252 (62.7%) | 212/252 (84.1%) |
| Continuing Rifaximin | — | 49/70 (70%) | 52/70 (74.3%) |
| Event | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 79/252 | 18/70 |
| Renal failure acuteRenal and urinary disorders | 30/252 | 5/70 |
| Hepatic cirrhosisHepatobiliary disorders | 7/252 | 7/70 |
| Liver transplantSurgical and medical procedures | 22/252 | 7/70 |
| Hepatic failureHepatobiliary disorders | 23/252 | 5/70 |
| AnaemiaBlood and lymphatic system disorders | 19/252 | 6/70 |
| AscitesGastrointestinal disorders | 15/252 | 2/70 |
| CellulitisInfections and infestations | 12/252 | 4/70 |
| Lobar pneumoniaInfections and infestations | 3/252 | 4/70 |
| Urinary tract infectionInfections and infestations | 8/252 | 4/70 |
| Event | New Rifaximin | Continuing Rifaximin |
|---|---|---|
| NauseaGastrointestinal disorders | 52/252 | 15/70 |
| Urinary tract infectionInfections and infestations | 50/252 | 15/70 |
| Oedema peripheralGeneral disorders | 48/252 | 13/70 |
| AscitesGastrointestinal disorders | 38/252 | 6/70 |
| HypokalaemiaMetabolism and nutrition disorders | 37/252 | 8/70 |
| VomitingGastrointestinal disorders | 34/252 | 8/70 |
| ConstipationGastrointestinal disorders | 33/252 | 4/70 |
| DiarrhoeaGastrointestinal disorders | 29/252 | 9/70 |
| DepressionPsychiatric disorders | 30/252 | 9/70 |
| FatigueGeneral disorders | 31/252 | 7/70 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | New Rifaximin | Continuing Rifaximin | Total |
|---|---|---|---|
| Mean | 57.6 ± 8.90 | 56.7 ± 9.36 | 57.4 ± 57.0 |
| Sex: Female, Male(Participants) | New Rifaximin | Continuing Rifaximin | Total |
|---|---|---|---|
| Female | 94 | 32 | 126 |
| Male | 158 | 38 | 196 |
Ran from Mar 2007 to primary completion in Dec 2010, 45 months.
Results were first posted in Aug 2019, 8 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →